JPRN-UMIN000009812招募中未知
Japan multicenter prospective study: FDG PET/CT in the assessment of advanced renal cell carcinoma treated with sorafenib - Japan multicenter prospective study: FDG PET/CT Assessment of advanced Kidney cancer study (J-PEAK )
Japan PET/CT Assessment of advanced Kidney cancer study group(J-PEAK group )0 个研究点目标入组 50 人开始时间: 2013年1月20日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who meet any of the following are excluded from the study. (1)Concurrent antitumor treatment other than sorafenib is given. (2)Prior treatment except cytokine therapies (3)Poorly-controlled diabetes mellitus (fasting blood glucose is more than 150 g/dL) (4)Pregnant and/or nursing woman, possibility of pregnancy (5)History of organ transplantation (including bone marrow transplantation) (6)History of malignancy except: (i)Curatively treated intraepithelial cervical cancer, basal cell carcinoma, superficial bladder cancer (Ta, Tis and T1). (ii)Patients who had been disease free more for than 3 years after curative therapy
研究者
相似试验
招募中
2 期
Japan multicenter prospective study: FDG-PET/CT as imaging biomarker to evaluate the response of Axitinib for Sunitinib failed metastatic renal cell carcinoma patients.renal cell carcinomaJPRN-UMIN000012542Yokohama City University50
已完成
Unknown
A retrospective study using 18F-FDG-PET/CT for the prediction of immunotherapy-related interstitial lung disease in lung cancer.Advanced or recurrent lung cancerJPRN-UMIN000053550iigata University Medical and Dental Hospital165
招募中
1 期
FDG-PET study for pulmonary MAC and CPAJPRN-jRCTs071190035Takazono Takahiro15
终止
2 期
Sequential FDG-PET (Positron Emission Tomography) and Induction Chemotherapy in Locally Advanced Adenocarcinoma of the Esophagogastric Junction (AEG)Adenocarcinomas of the Esophagogastric JunctionNCT01271322National Center for Tumor Diseases, Heidelberg
招募中
1 期
FDG-PET/CT versus conventional CT for response monitoring in metastatic breast cancer: A pilot study for a randomized clinical trial (MONITOR-PILOT)Metastatic breast cancerCTIS2023-506550-20-00Odense University Hospital30